Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma Bupivacaine Levels Following Pectoral Nerve Blocks
NCT03059498Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jun 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bupivacaine in pain (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoints: Peak plasma bupivacaine concentration at 90 minutes and Bupivacaine mean concentration at 90 minutes. Started Jun 2017; status: completed.
02
Drugs
bupivacaine
03
Conditions
pain
Beyond the preview
Go deeper on NCT03059498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03059498.